OBJECTIVES: To compare the total value of payer's expenditures on Victrelis (boceprevir) and Incivo (telaprevir) in patients with chronic HCV GT1 estimated in the manufacturers’ Budget Impact Analyses (BIAs) submitted with the reimbursement applications to AOTMiT  and actual expenditures of the National Health Fund (NHF). METHODS: Annual public payer’s expenditures estimated in manufacturers’ BIAs for Victrelis and Incivo and actual expenditures reported by the NHF were compared. RSSs were not taken into account. Analysed drugs were chosen on the basis of the same indication and financing through the same therapeutic programme in Poland. Actual expenditures and population size were taken from the financial reports of the NHF for the first and second year (actual data on 9 months for expenditures and 11 months for population size were extrapolated to one year) of reimbursement for each drug. RESULTS: For drugs Victrelis and Incivo in patients with chronic HCV genotype 1 infections, the sum of total expenditures estimated in BIAs submitted with the reimbursement applications was 145,38 million PLN in the first year and 164,49 million PLN in the second year, and they were higher than the actual expenditures reported by the NHF: 77,48 million PLN and 120,72 million PLN, respectively. The expenditures estimated in BIAs were overestimated by 88% in the first year of reimbursement and 36% in the second year of reimbursement. Population size estimated in BIAs in comparison to its actual size from the NHF reports was overestimated by 53% in the first year and 38% in the second year of reimbursement. CONCLUSIONS: In the case of drugs chosen for this analysis, total payer's expenditures estimated in BIAs submitted with the reimbursement applications were overestimated in comparison to the real life expenditures of the NHF in Poland.